The first 340B covered entity registration period of the year will be Jan. 1-18, 2022, for an effective start date of April 1, 2022.
Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies registered during the period
…
Just over 850 hospitals in the 340B program asked the federal government yesterday to appeal a judge’s Nov. 5 ruling that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and others use contract pharmacies. They
…
Groups representing 340B health centers, Ryan White clinics, and hospitals panned drug manufacturer Lilly’s recent decision to amend its prohibition on 340B pricing when providers use contract pharmacies to dispense drugs to patients.
Lilly told drug wholesaler AmerisourceBergen on
…
A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.
The infographic came to light Sunday. It includes
…
West Virginia U.S. Sen. Joe Manchin’s rejection Sunday of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.
Manchin said of the BBA bill on Dec. 19, “I cannot vote to
…
White House COVID-19 testing czar and long-time Democratic health policy expert Carole Johnson will become the next head of the U.S. Health Resources and Services Administration (HRSA) in January.
HRSA Acting Administrator Diana Espinosa announced Johnson’s selection this afternoon via
…
Drug manufacturer Lilly will let 340B covered entities buy medicines for shipment to an unlimited number of contract pharmacies if entities agree to provide claims-level data associated with such orders, a company spokesperson said late today.
340B hospitals and health
…
U.S. retail prescription drug spending hit $348.4 billion in 2020, constituting 8% of total health care expenditures, a new federal report shows.
The U.S. Centers for Medicare & Medicaid Services (CMS) yesterday published its annual national health care spending report
…
The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.
The committee released the
*Sign up for news summaries and alerts from 340B Report